Phenomenex to be Acquired by Danaher Corporation
Phenomenex (Torrance, California, USA) has announced that it will be acquired by Danaher Corporation (Washington, D.C., USA), a Fortune 150 science and technology company.
Phenomenex (Torrance, California, USA) has announced that it will be acquired by Danaher Corporation (Washington, D.C., USA), a Fortune 150 science and technology company. Phenomenex will continue to operate as a standalone company, and will retain the Phenomenex brand, its personnel, and site locations.
“Phenomenex is a widely recognizable brand that we are proud to say is highly respected and well established as providing high-quality consumables to the scientific community worldwide,” said Fasha Mahjoor, CEO of Phenomenex. “Joining Danaher will allow us to maintain the high pace of innovation that our customers and international distributors have come to expect from us. This is our opportunity to further expand our R&D activities, benefit our customers with a more diversified product portfolio, and reinforce our market leadership.”
Phenomenex employees more than 700 people worldwide and provides support into 92 countries through direct and distributor channels.
“We are thrilled to have Phenomenex join Danaher’s life sciences portfolio of businesses, which include Sciex, Beckman Coulter Life Sciences, Pall, Leica Microsystems, and Molecular Devices,” said Dan Daniel, Executive Vice President of Danaher. “The Danaher Business System (DBS) has a strong track record of helping businesses rapidly scale operations and create long-term customer value. We look forward to supporting the Phenomenex team in leveraging DBS tools for growth and welcoming them to our Life Sciences team.”
The transaction is expected to close by late 2016. For more information please visit www.phenomenex.com or www.danaher.com
Biopharmaceutical Characterization in the Age of Artificial Intelligence
May 13th 2025AI-powered tools are enhancing precision, efficiency, and decision-making in biopharmaceutical development. Recently, Jared Auclair and Anurag Rathore explored AI's evolving role in biopharmaceuticals in detail.
Determining Ways to Protect Honeybee Colonies with GC–MS
May 13th 2025A study conducted by the Agriculture Research Centre of Giza, Egypt, and Jilin Agricultural University in China, evaluated the efficacy of stinging nettle extract, nettle smoke, and formic acid in the controlling of Varroa mites, a major threat to honeybee colonies, with a focus on mite infestation reduction, honeybee mortality, and biochemical responses. Gas chromatography–mass spectrometry (GC–MS) was used to identify key bioactive compounds in the stinging nettle extract.
Evaluating the Accuracy of Mass Spectrometry Spectral Databases
May 12th 2025Mass spectrometry (MS) can be effective in identifying unknown compounds, though this can be complicated if spectra is outside of known databases. Researchers aimed to test MS databases using electron–ionization (EI)–MS.
